Kempner Capital Management’s GSK GSK Stock Holding History

Kempner Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-183,080	Closed	-$7.09M	–	48
2025 Q1	$7.09M	Hold	183,080	–	–	3.99%	4
2024 Q4	$6.19M	Buy	183,080 +107,648	+143%	+$3.88M	3.4%	7
2024 Q3	$3.08M	Hold	75,432	–	–	1.58%	31
2024 Q2	$2.9M	Hold	75,432	–	–	1.54%	30
2024 Q1	$3.23M	Sell	75,432 -4	-0%	-$165	1.75%	29
2023 Q4	$2.8M	Sell	75,436 -22	-0%	-$790	1.56%	31
2023 Q3	$2.73M	Buy	+75,458	New	+$2.68M	1.65%	29
2020 Q2	–	Sell	-24,928	Closed	-$1.18M	–	48
2020 Q1	$1.18M	Hold	24,928	–	–	1.03%	37
2019 Q4	$1.46M	Hold	24,928	–	–	0.95%	33
2019 Q3	$1.33M	Hold	24,928	–	–	0.9%	31
2019 Q2	$1.25M	Hold	24,928	–	–	0.82%	36
2019 Q1	$1.3M	Buy	24,928 +600	+2%	+$30K	0.86%	34
2018 Q4	$1.16M	Buy	24,328 +1,016	+4%	+$50K	0.8%	38
2018 Q3	$1.17M	Buy	+23,312	New	+$1.18M	0.75%	37

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Kempner Capital Management's GSK Position: Q2 2025 in Review

Kempner Capital Management sold out of GSK (GSK) in Q2 2025, closing a stake of 183,080 shares — an estimated $7.09M sold.

Kempner Capital Management first reported a position in GSK in Q3 2018 and held it in 14 quarters. The position peaked at $7.09M in Q1 2025. 891 funds tracked by Wall St. Rank hold GSK as of Q2 2025.

Kempner Capital Management reported no remaining GSK position as of Q2 2025 after selling out during the quarter.
Kempner Capital Management sold 183,080 GSK shares in Q2 2025, an estimated $7.09M.
Kempner Capital Management first reported a position in GSK in Q3 2018 and held it in 14 quarters.
Kempner Capital Management's GSK position peaked at $7.09M in Q1 2025.
891 funds tracked by Wall St. Rank held GSK as of Q2 2025.

Based on Kempner Capital Management's 13F filing for Q2 2025, filed 15 Jul 2025.